Lewis Richard A
Cedars-Sinai Medical Center, USA.
J Neurol Sci. 2013 Oct 15;333(1-2):93-8. doi: 10.1016/j.jns.2013.06.018. Epub 2013 Aug 9.
Over the past 40 years Dr. Robert Lisak has made important contributions to our understanding of the pathophysiology and therapy of myasthenia gravis. This review will touch upon some of his work as it discusses current therapies and the potential for new treatments based on the evolving knowledge of the underlying basis of the disease. The recognition of different immune mechanisms that can cause the phenotype that we acknowledge as myasthenia gravis coincides with the introduction of monoclonal antibodies and other new therapies that can target specific aspects of the disease. This has raised our hopes for treatments that will have less side effects and be more effective. In some cases these hopes have been realized. In other instances, the situation remains a "work in progress". Dr. Lisak's work and teachings remain cogent to our modern approach to this classic immunologic disease.
在过去的40年里，罗伯特·利萨克博士对我们理解重症肌无力的病理生理学和治疗方法做出了重要贡献。本综述将在讨论当前治疗方法以及基于对该疾病潜在病因不断发展的认识而产生的新治疗方法的可能性时，提及他的一些工作。对可导致我们所认可的重症肌无力表型的不同免疫机制的认识，与单克隆抗体及其他可针对该疾病特定方面的新疗法的引入同时出现。这让我们对副作用更小、疗效更佳的治疗方法充满了希望。在某些情况下，这些希望已经实现。而在其他情况下，情况仍在“进展之中”。利萨克博士的工作和教导对于我们现代治疗这种经典免疫疾病的方法仍然具有说服力。
